McPhadden Samac Tuovi LLP has commenced a proposed Pradaxa class action.
Pradaxa is a blood thinner used to prevent clotting in patients who suffer from atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes). It is also used by patients who have had hip and knee surgery.
There have been reports that Pradaxa causes excessive bleeding. There is no antidote that can be taken to stop excessive bleeding caused by Pradaxa. Bleeding caused by the drug that Pradaxa was intended to replace, Warfarin, can easily be stopped using a simple administration of vitamin K.
In the lawsuit, it is the plaintiff's position that patients should have been warned about the lack of an antidote. Claims are also made on behalf of others who say they suffered harm because of Pradaxa.
If you would like to receive further information about this proposed Pradaxa class action, please complete our online registration form.
CLICK HERE TO REGISTER
Pradax® is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co.. and is used here only to identify the product in question.